Advertisement
YOU ARE HERE: LAT HomeCollectionsSugen Inc
IN THE NEWS

Sugen Inc

FEATURED ARTICLES
BUSINESS
June 16, 1999 | Bloomberg News
Pharmacia & Upjohn Inc., the world's No. 1 maker of human growth hormone, agreed to buy biotechnology company Sugen Inc. in a $650-million stock transaction that would boost Pharmacia's development of cancer drugs. Pharmacia said it agreed to pay $31 worth of its stock for each share of Sugen. That price represents a 38% premium over South San Francisco-based Sugen's closing stock price Tuesday of $22.50. The acquisition could reduce earnings per share by as much as 2% next year, Pharmacia said.
ARTICLES BY DATE
BUSINESS
June 16, 1999 | Bloomberg News
Pharmacia & Upjohn Inc., the world's No. 1 maker of human growth hormone, agreed to buy biotechnology company Sugen Inc. in a $650-million stock transaction that would boost Pharmacia's development of cancer drugs. Pharmacia said it agreed to pay $31 worth of its stock for each share of Sugen. That price represents a 38% premium over South San Francisco-based Sugen's closing stock price Tuesday of $22.50. The acquisition could reduce earnings per share by as much as 2% next year, Pharmacia said.
Advertisement
BUSINESS
January 16, 1996
Amgen Inc. reached an agreement to cut off its four-year collaborative research project with Sugen Inc. a year early. Amgen, the large biotechnology company based in Thousand Oaks, struck a deal with Redwood City-based Sugen in 1992 to research neurological disorders in hopes of developing new drugs. But Amgen's chief executive, Gordon Binder, said that "Amgen's research priorities . . . have changed over the last three years, so this early conclusion makes sense for Amgen."
BUSINESS
October 9, 1996 | BARBARA MARSH, TIMES STAFF WRITER
Allergan Inc., continuing its strategy of hooking up with other companies to develop eye and skin therapies, said Tuesday it plans to invest $9 million with a tiny Redwood City company to pursue treatments to prevent blindness. The Irvine drug and medical devices company's partnership with Sugen Inc. is the third such deal that Allergan has lined up in the last four years with biotech companies in an effort to fuel future sales growth amid intense competition from its giant drug-industry rivals.
BUSINESS
October 9, 1996 | BARBARA MARSH, TIMES STAFF WRITER
Allergan Inc., continuing its strategy of hooking up with companies to develop eye and skin therapies, said Tuesday that it plans to invest $9 million with a tiny California company to pursue treatments to prevent blindness. The Irvine drug and medical devices company's partnership with Sugen Inc. of Redwood City is the third such deal Allergan has lined up in the last four years with biotech firms in a bid to fuel sales growth amid intense competition from its giant drug industry rivals.
BUSINESS
January 12, 1993 | JAMES F. PELTZ, TIMES STAFF WRITER
Amgen Inc., the biotechnology giant in Thousand Oaks, is collaborating with a fledgling Northern California company on developing new drug treatments for blood-related disorders. The four-year pact announced Monday between Amgen and Sugen Inc., based in Redwood City, calls for the companies to jointly develop and market any drugs they can commercialize, and to then share the profits. Amgen also purchased a 10% equity stake in privately held Sugen.
BUSINESS
October 9, 1996 | BARBARA MARSH, TIMES STAFF WRITER
Allergan Inc., continuing its strategy of hooking up with other companies to develop eye and skin therapies, said Tuesday it plans to invest $9 million with a tiny Redwood City company to pursue treatments to prevent blindness. The Irvine drug and medical devices company's partnership with Sugen Inc. is the third such deal that Allergan has lined up in the last four years with biotech companies in an effort to fuel future sales growth amid intense competition from its giant drug-industry rivals.
BUSINESS
May 6, 1997
Companies with highest ratios of market value to annual sales. A high "price-to-sales ratio" usually denotes a company that is expected to show explosive growth. *--* 4/18/97 1996 Price/ mkt. value revenue sales Rank Company (millions) (millions) ratio 1 Affymetrix Inc. $570 $12 48% 2 Yahoo Inc. 844 27 31 3 Redwood Trust Inc. 482 16 31 4 Advanced Tissue Sciences 408 17 24 5 Protein Design Labs Inc. 520 23 23 6 Gilead Sciences Inc. 689 33 21 7 Pixar Animation Studios 662 38 17 8 CNET Inc.
BUSINESS
April 29, 1996 | From Reuters
Millennium Pharmaceuticals Inc., hoping to capitalize on a firm market for biotechnology stocks as well as investor fascination with the prospects for an anti-obesity drug, plans to go public this week. The Cambridge, Mass.-based company will become the latest in the field of genomics--the study of genes--to go public in a market that has in recent months been receptive to biotech stocks.
BUSINESS
May 6, 1997
Companies ranked by net losses in 1996, including one-time charges that may not indicate routinely losing operations. *--* Rank Company 96 income (millions) 1 Apple Computer Inc. -$835 2 AST Research Inc. -418 3 Amdahl Corp. -327 4 Merisel Inc. -219 5 Calgene Inc. -145 6 Sizzler International -136 7 National Semiconductor -126 8 Advanced Micro Devices -115 9 SyQuest Technology Inc. -110 10 Argonaut Group Inc. -106 11 Trikon Technologies Inc. -94 12 Bay Networks Inc. -83 13 Cirrus Logic Inc.
BUSINESS
October 9, 1996 | BARBARA MARSH, TIMES STAFF WRITER
Allergan Inc., continuing its strategy of hooking up with companies to develop eye and skin therapies, said Tuesday that it plans to invest $9 million with a tiny California company to pursue treatments to prevent blindness. The Irvine drug and medical devices company's partnership with Sugen Inc. of Redwood City is the third such deal Allergan has lined up in the last four years with biotech firms in a bid to fuel sales growth amid intense competition from its giant drug industry rivals.
BUSINESS
January 16, 1996
Amgen Inc. reached an agreement to cut off its four-year collaborative research project with Sugen Inc. a year early. Amgen, the large biotechnology company based in Thousand Oaks, struck a deal with Redwood City-based Sugen in 1992 to research neurological disorders in hopes of developing new drugs. But Amgen's chief executive, Gordon Binder, said that "Amgen's research priorities . . . have changed over the last three years, so this early conclusion makes sense for Amgen."
BUSINESS
January 12, 1993 | JAMES F. PELTZ, TIMES STAFF WRITER
Amgen Inc., the biotechnology giant in Thousand Oaks, is collaborating with a fledgling Northern California company on developing new drug treatments for blood-related disorders. The four-year pact announced Monday between Amgen and Sugen Inc., based in Redwood City, calls for the companies to jointly develop and market any drugs they can commercialize, and to then share the profits. Amgen also purchased a 10% equity stake in privately held Sugen.
BUSINESS
June 15, 1993 | DON LEE, TIMES STAFF WRITER
Amgen Inc., the biotechnology giant in Thousand Oaks, has quietly struck a research deal with an obscure start-up company in South San Francisco, in effect buying the rights to a potential rival to Amgen's blockbuster anemia drug. The three-year agreement calls for Amgen to fund research and development at Arris Pharmaceutical Corp.
HEALTH
March 29, 1999 | THOMAS H. MAUGH II
Motherhood doubles a young woman's risk of developing heart disease, an increase in risk comparable to that caused by high cholesterol levels, according to researchers from the University of Minnesota. The increased risk arises from a decrease in the women's leisure-time physical activities, epidemiologist Kathryn Schmitz told an American Heart Assn. meeting in Orlando, Fla., on Friday.
Los Angeles Times Articles
|